(Q34607319)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19418833%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

review article

1 reference

title

[EAU guidelines on prostate cancer] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19418833%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19418833%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

Axel Heidenreich

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19418833%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Gunna Aus

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19418833%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Michel Bolla

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19418833%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Vsevolod B Matveev

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19418833%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Hans Peter Schmid

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19418833%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Filliberto Zattoni

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19418833%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

European Association of Urology

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19418833%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

publication date

1 February 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19418833%20AND%20SRC:MED&resulttype=core&format=json

Actas Urológicas Españolas

27 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19418833%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19418833%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19418833%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

113-126

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19418833%20AND%20SRC:MED&resulttype=core&format=json

EAU guidelines on prostate cancer

27 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Estimates of cancer incidence and mortality in Europe in 1995

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Familial prostate cancer in Sweden. A nationwide register cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Mendelian inheritance of familial prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Update on screening for prostate cancer with prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Value of routine transition zone biopsies in patients undergoing ultrasound-guided sextant biopsies for the first time

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Results of conservative management of clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Active surveillance for prostate cancer: for whom?

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Modeling prostate specific antigen kinetics in patients on active surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Radical prostatectomy versus watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

The discovery of the cavernous nerves and development of nerve sparing radical retropubic prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Adjuvant radiotherapy after radical prostatectomy: indications, results and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Current status of HIFU and cryotherapy in prostate cancer--a review

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Role of secondary hormonal therapy in the management of recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0210-4806%2809%2974110-5

7 January 2021

10.1016/S0210-4806(09)74110-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19418833%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference